NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis

Arrowhead Pharmaceuticals, Inc. (ARWR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ARWR

$86.34

−$0.15 (−0.17%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ARWR with… →

ARWR Key Statistics

As of Sep 4, 2026
Trading
Open
$85.87
Previous Close
$86.49
Day's Range
84.20–86.96
52-Week Range
27.10–95.49
Volume
757.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.28
Valuation
Market Cap
$12.20B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
18.22
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.28
Financials (FY)
Revenue (FY)
$829.45M+23258.15%
Net Income (FY)
−$1.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
−47.79%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
141.25M
1-Year Return
+208.36%
Dividend and dates
Earnings Date
November 24, 2026estimated
Avg Volume
2.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ARWR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+30.05%
2025+253.14%
2024−38.56%
2023−24.56%
2022−38.82%
2021−13.59%
2020+20.97%
2019+410.71%
2018+237.50%
2017+137.42%
2016 (partial year)−73.73%

As of September 4, 2026.

ARWR Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$829.45M−$1.63M−0.2%
2024$3.55M−$599.49M−16882.4%
2023$240.74M−$205.28M−85.3%
2022$243.23M−$176.06M−72.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$829.45M—$98.35M−$1.63M−0.2%
2024$3.55M—−$601.08M−$599.49M−16882.4%
2023$240.74M—−$205.00M−$205.28M−85.3%
2022$243.23M—−$178.51M−$176.06M−72.4%

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

ARWR Valuation vs Biotechnology Median

Median of 656 stocks
MetricARWRBiotechnology medianvs median
P/S ratio18.2215.2619% above
Profit margin−47.79%0.00%47.8 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Arrowhead Pharmaceuticals, Inc. (ARWR) is capitalised at $12.20B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 711 employees.

ARWR last closed at $86.34 on September 4, 2026. That is −$0.15 (−0.17%) against the previous close. Over the past 52 weeks the price has ranged from $27.10 to $95.49. The latest close sits 218.6% above that 52-week low.

Financial Health

In fiscal 2025, Arrowhead Pharmaceuticals, Inc. reported revenue of $829.45M. That is +23,258.15% against the prior fiscal year, when revenue was $3.55M. The same year closed with a net loss of $1.63M. The reported profit margin is −47.79%. That is 47.8 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −2.28.

Across the 4 fiscal years on file, revenue moves from $243.23M in 2022 to $829.45M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 18.22 times revenue. On price-to-sales that is 19.35% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.28. Daily returns over the trailing 10 years annualize to a volatility of 74.05%. The trailing one-year price return is +208.36%. Measured over 10 years, that is +28.29% a year compounded.

Growth & Income

No dividend is on file for ARWR.

So far in 2026 the price is +30.05%. Across the complete calendar years on file, 2019 returned +410.71% and 2022 returned −38.82%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Arrowhead Pharmaceuticals, Inc. (ARWR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Arrowhead Pharmaceuticals, Inc. ARWR $12.20B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Arrowhead Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Visit website →